Roivant Sciences Ltd (STU:87S)

€ 10.585 -0.005 (-0.05%) Market Cap: 7.93 Bil Enterprise Value: 3.06 Bil PE Ratio: 2.07 PB Ratio: 1.57 GF Score: 41/100

Q1 2025 Roivant Sciences Ltd Earnings Call Transcript
Aug 08, 2024

€9.18 (-1.38%)

Earnings
Q4 2024 Roivant Sciences Ltd Earnings Call Transcript
May 30, 2024

€9.68 (-2.54%)

Earnings
Q3 2024 Roivant Sciences Ltd Earnings Call Transcript
Feb 13, 2024

€10.1 (+1.51%)

Earnings
Roivant Sciences Ltd at Guggenheim Healthcare Talks Biotechnology Conference Transcript
Feb 07, 2024
Roivant Sciences Ltd at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Roivant Sciences Ltd at Piper Sandler Healthcare Conference Transcript
Nov 30, 2023
Roivant Sciences Ltd at Evercore ISI HealthCONx Conference Transcript
Nov 29, 2023
Roivant Sciences Ltd at Jefferies London Healthcare Conference Transcript
Nov 15, 2023
Q2 2024 Roivant Sciences Ltd Earnings Call Transcript
Nov 13, 2023

Earnings
Roivant Sciences Ltd at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Roivant Sciences Ltd at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Roivant Sciences Ltd at Citi BioPharma Conference Transcript
Sep 07, 2023
Q1 2024 Roivant Sciences Ltd Earnings Call Transcript
Aug 14, 2023

€10.5 (-0.94%)

Earnings
Q4 2023 Roivant Sciences Ltd Earnings Call Transcript
Jun 28, 2023

€8.1 (-1.82%)

Earnings
Roivant Sciences Ltd to Review Results From the Chronic Period of TUSCANY-2 Investor Call Transcript
Jun 22, 2023
Roivant Sciences Ltd at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Roivant Sciences Ltd at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Roivant Sciences Ltd at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Roivant Sciences Ltd at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Roivant Sciences Ltd to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis Call Transcript
Mar 15, 2023
Q3 2023 Roivant Sciences Ltd Earnings Call Transcript
Feb 13, 2023

Earnings
Roivant Sciences Ltd at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Roivant Sciences Ltd at Goldman Sachs CEOs Unscripted Conference Transcript
Jan 05, 2023
Roivant Sciences Ltd to Announce Positive Results From the Induction Period of the TUSCANY-2 Call Transcript
Jan 04, 2023
Q2 2023 Roivant Sciences Ltd Earnings Call Transcript
Nov 14, 2022

Earnings
Roivant Sciences Ltd at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Roivant Sciences Ltd Investor Day 2022 Transcript
Sep 28, 2022
Q1 2023 Roivant Sciences Ltd Earnings Call Transcript
Aug 15, 2022

Earnings
Q4 2022 Roivant Sciences Ltd Earnings Call Transcript
Jun 28, 2022

Earnings
Roivant Sciences Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Roivant Sciences Ltd Tapinarof FDA Approval Investor Call Transcript
May 24, 2022
Roivant Sciences Ltd at UBS Global Healthcare Conference Transcript
May 23, 2022
Roivant Sciences Ltd to Provide Update Regarding Initiation of Patent Litigation Against Moderna - Conference Call Transcript
Feb 28, 2022
Q3 2022 Roivant Sciences Ltd Earnings Call Transcript
Feb 14, 2022

Earnings
Roivant Sciences Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Q2 2021 Roivant Sciences Ltd Earnings Call Transcript
Nov 15, 2021

Earnings
Q2 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences Transcript
Nov 01, 2019
Sumitomo Dainippon Pharma Co Ltd and Roivant Sciences Ltd Memorandum of Understanding for Strategic Alliance Call Transcript
Sep 06, 2019

Q4 2024 Roivant Sciences Ltd Earnings Call Transcript

May 30, 2024 / 12:00PM GMT

Release Date Price: €9.68 (-2.54%)

Transcript 10-K8-K

Operator

Good day, and thank you for standing by. Welcome to the Roivant fourth-quarter-2023 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Everybody, please go ahead.

Abby Beier

Roivant Sciences Ltd. - Principal, Strategic Finance

Good morning, and thanks for joining today's call to review Roivant's financial results for the fourth quarter and fiscal year ended March 31, 2024, along with the business update. I'm Abby Beier with Roivant. Presenting today, we have Matt Gline, CEO of Roivant.

For those dialing in via the conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at investors.roivant.com. We'll also be providing the slide numbers as we present to help you follow along.

I'd like to remind you that we'll be making certain forward-looking statements during today's presentations. We strongly encourage you to review the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.